Melanoma: talimogene laherparepvec doubles ORR in phase 2 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Talimogene laherparepvec plus ipilimumab is associated with greater efficacy than ipilimumab in an open-label phase 2 trial of patients with advanced, unresectable melanoma.

Why this matters

  • First randomized trial to evaluate the addition of an oncolytic virus to a checkpoi...